Tags Posts tagged with "APHQF"

APHQF

0 5120

@WolfOfWeedST

With the Trump Administration in complete disarray and touting debunked information about Cannabis & Opioid connections we at MarijuanaStocks.com decided to play a little game of devils advocate. The fact remains that the Trudeau administration remains progressive and is doing what all governments should be doing i.e. listening to its people. Canadians are in overwhelming support of legal cannabis markets which is why they legalized medical marijuana last year. This year the country plans on legalizing recreational use in an effort to crush black markets, create jobs, industry and position itself as a worldwide leader in cultivation. With a completely legal market Canada will face one major issue that will reap major benefits to public cultivation companies. That issue being one of supply and demand. Already operating at a deficit and coupled with an approval process by Health Canada that can take years we foresee investors sending their capital north of the border unless they are invested in companies insulated by restrictions on the recreational markets. Those US companies being: Construction for Cultivation, manufacturers of products, companies monetizing industrial Hemp’s many uses, CBD manufacturers, technology & media services (like us).

One of the highly anticipated events of 2017 is the tabling of legislation as it relates to a legal recreational cannabis program in Canada. This development is expected to take place in the Spring.

During December, a federal task force released its long-awaited recommendations relating to the legalization of recreational marijuana. The report was prepared by a committee comprised of nine members who have worked together since June.

All Eyes on Legislation this Spring

When Canada legalizes recreational marijuana, demand is going to increase significantly, however it will take time for the program to be up and running. For this reason, Canadian licensed medical cannabis producers have been aggressively raising capital to make acquisitions and to increase production capacity.

One of the largest fundamental changes within the Canadian cannabis sector over the last year relates to the amount of capital entering the industry as well as the source of the capital. The capital entering the industry is not only larger but smarter too; these investors and firms are long-term holders that see the bigger picture.

Five Opportunities to Watch

The Canadian cannabis industry has continued to be a bright spot for cannabis investors and 2017 has already provided investors with strong investment returns.

This sub-sector of the cannabis industry has been on fire since July 2016 and the increased interest has been fueled by anticipation of Canada becoming the first G-7 nation to legalize recreational cannabis.

Although the Canadian cannabis industry offers investors a lot of opportunity, it does not come without risk. Many of the companies levered to this sector have seen a significant rally over the last six months while some have not fared as well.

We want highlight five Canadian cannabis stocks that should be on every investors radar. From

The Green Organic Dutchman’s second round of financing closes today at 5pm and investors can still reach out to support@sbpartners.io if they still want to access this opportunity.

Terms of the offering are as follows: The company is selling units at $1.15 CAD per unit and the minimum purchase level is 5,000 units. Each unit consists of one common share and one full share purchase warrant. Each warrant provides the investor to purchase shares of The Green Organic Dutchman at $2.15 for the next two-years no matter what price the shares are trading at.

The Green Organic Dutchman produces farm grown pharmaceutical grade organic cannabis. The company has differentiated itself from the competition by producing high-quality organic cannabis that sells for a higher price and has better profit margins. The company is led by a management team that has a proven track record of success with licensed Canadian medical cannabis producers such as OrganiGram and Emblem Corp.

Aphria (APH.V: TSX Venture) (APHQF: OTC) has been one of the top performers this year and the shares are up approximately 30% YTD. The shares moved considerably higher after the company received conditional approval to up-list on the TSX exchange and we remain favorable on the company’ long-term outlook.

In early February, Aphria announced a $50 million private placement at $5.00 a share and this transaction is expected to close this week. The company expects that 80% of the net proceeds will be allocated towards the currently unfunded portion of Part IV Expansion, with the balance being allocated towards strategic investments.

The Part IV expansion will increase Aphria’s capacity from 300,000 to 1 million square feet. In addition, the company’s infrastructure will grow to over 250,000 square feet which is necessary to service the expected 70,000 kilograms of eventual annualized harvests. The project includes 700,000 square feet of Dutch style greenhouses, 230,000 square feet of infrastructure, including new Level 9 vaults, automation for all the greenhouses, processing areas, warehouse facilities, a 15 MW power and heat co-generation facility and security consistent with ACMPR standards.

Aphria anticipates completion of Part IV within 12 months, Health Canada approvals within 4 months of completing the expansion and first harvest within 4 months after such approvals.

In December 2016, Aphria invested $8.4 million in Canabo Medical Inc. (CMM.V: TSX Venture) (CAMDF: OTC) at $1.40 a share. Canabo is another stock we are very favorable as the shares trade at an almost 40% discount to the level at which Aphria invested at.

Canabo owns and operates the largest line of medical cannabis clinics in Canada and we expect to see the company continue to expand its footprint across Canada.

CMM.V is trading at $0.85 after the shares rallied more than 13% on above-average volume. We highlighted the company last month as an attractive opportunity and continue to see upside to current levels. The company’s United States symbol, CAMDF is trading below $0.67 after a 16.4% rally and we continue to see upside to these levels.

PharmaCan Capital (MJN: TSX Venture) (PRMCF: OTC) has the top performing licensed Canadian medical cannabis producer this year and the shares are up 92.6% YTD. The company does business as Cronos Group and in 2016, it sold one of its properties to NYSE-traded Innovative Industrial Properties (IIPR).

The shares were under pressure last week after the company announced a $15 million private placement at $2.25 a share. MJN.V quickly bounced back and rallied more than 40% over the few trading days.

The company’s wholly-owned subsidiary, In The Zone, recently received approval from Health Canada to sell medical cannabis. This comes while its other wholly-owned subsidiary, Peace Naturals is positioned to capitalize on the recent medical cannabis legislation in Germany through its export relationship with Pedanios GmbH.

Although the shares have recent run significantly higher, we have become increasingly favorable on the company over the last quarter and continue to monitor trading closely. Become a Technical420 Premium Member to keep up with our analysis.

Canopy Growth Corp. (WEED.TO: TSX) (TWMJF: OTC) continues to be the Canadian medical cannabis leader and we view the company as one of the best long-term cannabis investments.

The company recently completely the acquisition of Mettrum Health, which significant expanded its product line and led to a surge in revenue. The market did not initially respond favorable to Canopy earnings report and the shares recorded its largest drop of the year.

During the quarter, Canopy Growth recorded $3 million in net income off $9.8 million in revenue and total revenue increased 15% when compared to the prior quarter and 180% when compared to the same period last year.

During the quarter, the company sold 1,245 kilograms and kilogram equivalents at an average price of $7.36 per gram, up from 462 kilograms at an average price of $7.34 per gram during the prior year period.

The company recorded strong growth on pretty much all metrics and as of December 31st , Canopy Growth reported to have over 29,000 registered patients which is more than 260% higher than the number of patients as of December 31, 2015.

Canopy has recaptured most of its losses and we continue to remain favorable and monitor trading activity closely. WEED.TO recently traded into the $13.20 range and the shares are currently trading at $12.64. We remain favorable on Canopy Growth and this company should be on every cannabis investor radar screen.

1 4837

Last month, on October 3, 2016, we published an article titled Past, Present, & Future of Canadian Marijuana Stocks where we expressed our bullish sentiment on the Canadian marijuana sector and identified a list of stocks to consider. In the article, we named 6 companies to focus on. Within one month of publishing the article, those 6 stocks have seen combined 480% in total gains as of November 2nd, 2016. This article would have been out a week ago if our new intern knew how to hit the publish button correctly. Regardless, the gains and the charts do not lie as they tell the tale of the ticker tape.
The Canadian government is planning to legalize cannabis in spring 2017 and the number of Canadian medical marijuana patients is expected to more than double. This will tilt the supply and demand scale for medical marijuana largely in favor of demand. We do not believe this recent rally to be just a pre-election “hype rally.” This is the coming out party for an industry with an immensely bright future and staying power.
Licensed medical cannabis producers have raised more than $100 million in the past couple months to be used to support growth initiatives like mergers and acquisitions and facility expansions to better meet the increased demand. The investment opportunities in the legal cannabis industry have proven extremely lucrative to informed investors. Let’s take a look at the 6 companies we highlighted in our October 3rd article to see how they are doing today and where they could go from here.
1. Canopy Growth Corporation (CGC.TO)(TWMJF)

pic1

 

 

Canopy Growth is the largest legal medical marijuana producer in Canada and has been one of the most attractive investment opportunities in the cannabis sector since going public in 2014. CGC.TO hit a high of $7.35 on October 20th for an 80.5% gain from our initial article publication. The stock closed trading today at $6.55, still up 61%. TWMJF (the US OTC listing) still sits up 58% today.

Canopy Growth is the medical marijuana industry leader. Aside from individual news announcements, expect other marijuana companies to follow the strength and/or weakness of CGC.TO. After a healthy pull-in, the stock held support around $5.50 and remains in a strong uptrend.

2. Aurora Cannabis (ACB.CN)(ACBFF)

pic2

Aurora Cannabis is one of the fastest growing licensed medical cannabis producers in Canada. One thing to know about them is that they recently did a private placement for $20,000,000 and ended up being over-subscribed by a few million dollars. They have one of the industry’s more impressive facilities and is partly why we added Aurora to our Focus List in June 2016. Since July of 2016, ACBFF is up roughly 125%. And since our article publication on October 3rd, ACBFF gained as much as 78% and closed trading today around $1.66, still up nearly 57%.

ACBFF is forming a bullish pennant pattern that would trigger a long through the $1.77 area or a sell below the $1.50 area. A breakdown of the pattern could see ACBFF test the gap it put in place on October 5th. However, a healthy consolidation in this range would give the moving averages time to catch up while the stock takes a breather before a possible move higher into $2.00 land.

3. Aphria Inc. (APH.V)(APHQF)

pic3

Aphria showed the smallest gain potential of all the companies listed in our October 3rd article. A max 17% gain was possible while APH closed trading today at $3.80, still up 10%.

APH.V has put in a double top at $4.00 that would act as a trigger long if broken to the upside. Support is in place around $3.30 after being tested multiple times and holding over the past month. A break below this support could see Aphria test its next support area around $3.00.

4. OrganiGram Holdings (OGI.V)(OGRMF)

pic4

Organigram is the second largest licensed producer in Canada and was the first to report positive cash flow. Organigram could be considered the second industry leader behind Canopy Growth so it is no surprise to see the two share very similar chart patterns. OGI.V hit a high of $3.11 on October 19th for a 75% gain from our article publication and closed trading today at $2.76, still up 55%.

Like CGC.TO, Organigram remains in an uptrend. Support was put in around the $2.30 area after a healthy pull-in. Look for OGI.V and CGC.TO to show strength and weakness together. It would be rare for one to show strength while the other weakness (unless for an individual press release good or bad).

5. Arcturus Growthstar Technologies (AGS.CN)(AGSTF)

pic5

Arcturus Growthstar Technologies is a company that may play a huge part in the expansion of the Canadian cannabis market and its ability to meet the increased demand. Their Controlled Environment Agriculture technology helps producers minimize land, water, and energy output while increasing crop turnover and capacity.

We also published a Connect the Dots piece on AGSTF on October 4th to introduce our readers to a new company that we believed was worth considering. The stock gained a remarkable 180% in just three days before pulling back in to still be up 34%. For those unfamiliar with Arcturus, we recommend going back and reading our Connect the Dots piece published on October 4th.

It’s important to discuss why such a sharp pullback after the 180% run. And we believe there to be a couple reasons.

➢ The stock is a very new issue and, therefore, does not have as much of a trading history as some of the other companies on this list. The trading float is also much smaller than the Canadian companies that came public in 2014 or sooner. This can sometimes result in over exaggerated or over extended price movements in both directions because of lack of stock available in the open market.

➢ The Company had a million dollars of warrants exercise at $0.15 to raise additional capital to support their rapid growth and expansion. Although it brought cash to the company, it added pressure to the market that aided in the sharp pull-in. But with that exercise now behind them, Arcturus can focus on putting that money to work.

Don’t forget, in October 2015, one year ago, Organigram traded for less than $0.30 a share, too. Fast forward to October 2016 and the stock now trades for $2.75 a share. Good management can build shareholder value pretty quickly when appropriating funds correctly and progressing through their business plan. And the management team behind Arcturus is one of the main reasons why we decided to issue a Connect the Dots piece on the company.

6. Cronos Group (formerly PharmaCan Capital Corp.) (MJN.V)(PRMCF)

pic6

Cronos Group is an investment firm and holding company for Licensed Producers under Canada’s Marihuana for Access to Cannabis for Medical Purposes Regulations (“ACMPR”). With interests in five licensed producers and three license applicants, Cronos Group is focused on building iconic brands providing patients with compassionate, personalized care. The stock hit a high of $1.35 on October 6th for a 45% gain from our article publication and currently still sits up 29%.

Similar to Aurora Cannabis, Cronos has developed a bullish pennant pattern. The $1.30 area would be a trigger long while the $1.13 area a trigger sell. A breakout could see MJN.V run to the $1.60 area while a breakdown would most likely retest the $1.00 mark, maybe lower.
Conclusion

The timing of our article titled Past, Present, & Future of Canadian Marijuana Stocks was spot on. We nailed breakout points in most of the major Canadian cannabis companies. After publication, the 6 stocks highlighted gained a combined total of 480% and each one remains higher today.

As we mentioned in the article, we believe the Canadian market to be much further along in development than the US market; although the US market is making major strides that we will discuss in a future article. The overall marijuana industry is experiencing a strong rally, both in the US and Canada. And we believe the companies discussed in this piece to have long-term investment potential, not just a quick trade.

0 1904

Aphria and MassRoots Partner in One of First International Collaborations between Cannabis Companies

Aphria Inc. (“Aphria” or the “Company”) (TSX-V: APH or USOTCQB:  APHQF) one of the leading Canadian licensed producers of medical cannabis, and MassRoots, Inc. (MSRT), one of the largest technology platforms for the cannabis industry, are pleased to announce they have entered into one of the first international partnerships between cannabis companies.  Under the terms of the agreement, MassRoots will help build awareness of the Aphria brand amongst its Canadian userbase.  Aphria will compensate MassRoots a cash fee (in U.S. dollars) per patient it refers.

“We are thrilled to partner with Aphria to help expand their patient base while opening a new revenue stream for our business,” stated MassRoots CEO Isaac Dietrich. “As a technology platform, MassRoots is available in every state and country that regulates the production of cannabis and we could not be more excited to have a partner of Aphria’s caliber in the Canadian market.”

“This partnership with MassRoots offers a fresh, innovative way to expand Aphria’s patient base while helping to grow our digital presence,” stated Aphria CEO Vic Neufeld. “MassRoots has the potential to be the leading technology platform in the cannabis sector and we look forward to leveraging their distribution channels and data to optimize our operations.”

On Monday, October 17, 2016, Aphria, Inc. invested $250,000 USD in MassRoots by purchasing 500,000 shares of MassRoots common stock, along with receiving warrants to purchase an additional 500,000 shares at $0.90 per share, valid until October 17, 2019 under MassRoots’ Registered Offering declared effective by the United States Securities and Exchange Commission on August 11, 2016.  The partnership with MassRoots and the related equity investment remain remain subject to regulatory approvals, including the approval of the TSX Venture Exchange.

About MassRoots

MassRoots is one of the largest and most active technology platforms for cannabis consumers, businesses and activists with over 900,000 registered users. It is proud to be affiliated with the leading organizations in the cannabis industry, including the ArcView Group and National Cannabis Industry Association. MassRoots has been covered by Fox Business, CNBC, Fortune, Denver Post, and The Financial Times. For more information, please visit MassRoots.com/Investors.

About Aphria

Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. We are the first public licenced producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters. For more information, visit www.Aphria.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, the growth of MassRoots’ business, the growth of Aphria’s business, potential partnerships, new features, related business strategies, statements with respect to internal expectations, estimated margins, expectations for future growing capacity, the expected growth of production facilities in North America, any commentary related to the legalization of marijuana and the timing related thereto, and expectations with respect to future production costs. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of Aphria or MassRoots to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements